Literature DB >> 11180502

Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways.

K Sakai1, X M Gao, T Hashimoto, C A Tamminga.   

Abstract

The effects of three chronically administered antipsychotic drugs on selected neurochemical markers of dopaminergic and GABAergic transmission were compared within the cerebral regions making up the basal ganglia-thalamocortical parallel processing neuronal pathways. All three drugs reduce psychosis in humans, whereas only haloperidol, but not olanzapine or sertindole, induce purposeless oral chewing movements (CMs) in rats or cause high rates of parkinsonism or tardive dyskinesia in humans. Male Sprague Dawley rats were treated with haloperidol, sertindole, or olanzapine delivered in drinking water for 6 months at doses which produce drug plasma levels in rat in the human therapeutic range. Results show the expected dopamine D2 receptor upregulation in striatum predominantly with haloperidol, although mild D2 upregulation was apparent in striatum after olanzapine. GAD67 mRNA was increased in striatum and decreased in globus pallidus by haloperidol and sertindole, but not by olanzapine. In the substantia nigra pars reticulata (SNR), both olanzapine and sertindole failed to induce GABA(A) receptor upregulation or D1 receptor downregulation, but haloperidol did both, confirming a previous report. In thalamus, all three drugs increased GAD expression in the reticular nucleus, whereas only haloperidol decreased GABA(A) binding in the mediodorsal nucleus, actions consistent with a reduction in nigrothalamic, GABA-mediated neural transmission. These results are consistent with the idea that the two new antipsychotics tested have mild and regionally restricted actions within the basal ganglia nuclei and a common action on increasing GAD expression in the reticular nucleus of the thalamus (RtN). Haloperidol, in contrast, has a broad and potent action in basal ganglia, causing changes in SNR and in the mediodorsal nucleus, while also altering GAD mRNA in RtN, potentially reflective of its dyskinetic and antipsychotic actions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11180502     DOI: 10.1002/1098-2396(200102)39:2<152::AID-SYN6>3.0.CO;2-F

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  8 in total

1.  Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.

Authors:  E C Muly; J R Votaw; J Ritchie; L L Howell
Journal:  J Pharmacol Exp Ther       Date:  2012-01-03       Impact factor: 4.030

2.  Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.

Authors:  Emma Perez-Costas; Paolo Guidetti; Miguel Melendez-Ferro; Joyce J Kelley; Rosalinda C Roberts
Journal:  J Neural Transm (Vienna)       Date:  2008-01-11       Impact factor: 3.575

3.  Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole.

Authors:  Felice Iasevoli; Carmine Tomasetti; Federica Marmo; Daniele Bravi; Jørn Arnt; Andrea de Bartolomeis
Journal:  Psychopharmacology (Berl)       Date:  2010-07-23       Impact factor: 4.530

4.  A systematic review of TMS and neurophysiological biometrics in patients with schizophrenia.

Authors:  Meng di Hou; Viviana Santoro; Andrea Biondi; Sukhi S Shergill; Isabella Premoli
Journal:  J Psychiatry Neurosci       Date:  2021-12-21       Impact factor: 6.186

5.  Aripiprazole differentially regulates the expression of Gad67 and γ-aminobutyric acid transporters in rat brain.

Authors:  Nina Peselmann; Andrea Schmitt; Peter J Gebicke-Haerter; Mathias Zink
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-12       Impact factor: 5.270

Review 6.  The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia.

Authors:  Kuei Y Tseng; R Andrew Chambers; Barbara K Lipska
Journal:  Behav Brain Res       Date:  2008-12-03       Impact factor: 3.332

Review 7.  Treatment of neurolept-induced tardive dyskinesia.

Authors:  Stacey K Jankelowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

8.  Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.

Authors:  Lior Greenbaum; Stefano Goldwurm; Polina Zozulinsky; Tzuri Lifschytz; Oren S Cohen; Gilad Yahalom; Roberto Cilia; Silvana Tesei; Rosanna Asselta; Rivka Inzelberg; Yoav Kohn; Sharon Hassin-Baer; Bernard Lerer
Journal:  J Mol Neurosci       Date:  2013-05-12       Impact factor: 3.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.